Cadoret-Manier Onaiza
Known title: EVP, Chf Corp Dev and Cml OffcCIK: 0001799355
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Cathie Wood adds to Ionis position amid RNA sector interest. Cathie Wood has increased her holdings in Ionis Pharmaceuticals as part of a broader bet on two stocks. This move highlights continued investor interest in RNA therapeutics, a sector currently drawing attention for its innovation potential. While the stock is trading near its 52-week low, the average analyst target remains significantly higher than the current price.
Transaction History
| ARDX | ▲ Buy | Grant | 26,455 | $0 | 6/16/2026 | View on chart |
| ARDX | ▲ Buy | Grant | 41,551 | $0 | 6/18/2025 | View on chart |
| IONS | ▼ Sell | Open Market | 2,125 | $105K | 2/2/2024 | View on chart |
| IONS | ▲ Buy | Grant | 4,140 | $0 | 2/1/2024 | View on chart |
| IONS | ▼ Sell | Open Market | 5,564 | $281K | 1/17/2024 | View on chart |
| IONS | ▲ Buy | Option Exercise | 15,062 | $0 | 1/16/2024 | View on chart |
| ARDX | ▲ Buy | Grant | 12,755 | $0 | 6/15/2023 | View on chart |
| IONS | ▼ Sell | Open Market | 2,582 | $94K | 4/18/2023 | View on chart |
| IONS | ▲ Buy | Option Exercise | 5,667 | $0 | 4/17/2023 | View on chart |
| IONS | ▼ Sell | Open Market | 1,451 | $59K | 2/6/2023 | View on chart |
| IONS | ▲ Buy | Grant | 4,140 | $0 | 2/3/2023 | View on chart |
| IONS | ▼ Sell | Open Market | 3,748 | $148K | 1/18/2023 | View on chart |
| IONS | ▲ Buy | Option Exercise | 10,197 | $0 | 1/17/2023 | View on chart |
| ARDX | ▲ Buy | Grant | 91,240 | $0 | 6/15/2022 | View on chart |
| IONS | ▲ Buy | Option Exercise | 5,667 | $0 | 4/18/2022 | View on chart |
| IONS | ▼ Sell | Tax Withholding | 1,960 | $80K | 4/18/2022 | View on chart |
| IONS | ▲ Buy | Option Exercise | 6,057 | $0 | 1/18/2022 | View on chart |
| IONS | ▼ Sell | Tax Withholding | 2,305 | $69K | 1/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Ardelyx shares IBSRELA real-world data at ACG 2026
Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.
Ardelyx shares IBSRELA real-world data at ACG 2026. Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.